以Sam Altman为首的生物技术公司旨在利用CRISPR防止胚胎遗传疾病,引发道德和安全辩论。 Biotech firms led by Sam Altman aim to use CRISPR to prevent inherited diseases in embryos, sparking ethical and safety debates.

以Sam Altman等人物为后盾的生物技术初创企业正在推进CRISPR和基础编辑技术,以预防胚胎遗传性疾病,旨在根除镰状细胞贫血症和亨廷顿病等疾病。 Biotech startups backed by figures like Sam Altman are advancing CRISPR and base-editing technologies to prevent inherited genetic diseases in embryos, aiming to eradicate conditions like sickle cell anemia and Huntington’s disease. 治疗病人镰状细胞的CRISPR疗法虽获批准, 但并不阻止疾病传播。 While CRISPR therapies are approved for treating sickle cell in patients, they don’t stop disease transmission. 但科学家警告风险, 如非目标突变, 以及对“设计婴儿”的道德担忧, 特别是对于多元基因筛查的兴趣日益浓厚。 Companies say they’re focused on safety and transparency, but scientists warn of risks like off-target mutations and ethical concerns over "designer babies," especially with rising interest in polygenic screening. 在美国、英国和许多国家, 人类胚胎的编辑仍然是非法的, 科学界对它的准备程度有分歧。 Human embryo editing remains illegal in the U.S., U.K., and many countries, and the scientific community is divided on its readiness.